Pulmonx (LUNG)

• Market cap: $122M
• 1 day: -3.50%
• 5 days: -4.42%
• 1 month: -8.73%
• 3 months: -57.02%
• 6 months: -50.33%
• Year to date: -53.53%
• 1 year: -51.60%
• 5 years: -92.29%
• 10 years: -92.29%
• Sector: Healthcare
• Industry: Medical Devices

About: Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Employees: 291

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

32% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 31

0.01% more ownership

Funds ownership: 90.84% [Q4 2024] → 90.84% (+0.01%) [Q1 2025]

0% less capital invested

Capital invested by funds: $244M [Q4 2024] → $243M (-$240K) [Q1 2025]

3% less funds holding

Funds holding: 118 [Q4 2024] → 114 (-4) [Q1 2025]

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

96% less call options, than puts

Call options by funds: $76K | Put options by funds: $1.85M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4.15 37% upside
• Avg. target: $11.29 273% upside
• High target: $17 461% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Citigroup Joanne Wuensch	37% upside $4.15	Neutral Maintained	22 May 2025
Canaccord Genuity Jon Young	395% upside $15	Buy Maintained	1 May 2025
Piper Sandler Jason Bednar	197% upside $9	Overweight Reiterated	1 May 2025
D. Boral Capital Jason Kolbert	461% upside $17	Buy Maintained	1 May 2025